| scholarly article | Q13442814 |
| P8150 | COVIDWHO ID | covidwho-101990 |
| P6179 | Dimensions Publication ID | 1126837604 |
| P356 | DOI | 10.1038/S41577-020-0321-6 |
| P932 | PMC publication ID | 7187142 |
| P698 | PubMed publication ID | 32317716 |
| P50 | author | Akiko Iwasaki | Q19958193 |
| P2093 | author name string | Yexin Yang | |
| P2860 | cites work | Global profiling of SARS-CoV-2 specific IgG/ IgM responses of convalescents using a proteome microarray | Q88978271 |
| Viral Kinetics and Antibody Responses in Patients with COVID-19 | Q88978934 | ||
| Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications | Q95611267 | ||
| Structural Insights into the Mechanisms of Antibody-Mediated Neutralization of Flavivirus Infection: Implications for Vaccine Development | Q27488364 | ||
| Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses | Q33756740 | ||
| The spike protein of SARS-CoV--a target for vaccine and therapeutic development | Q34015988 | ||
| Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins | Q34041594 | ||
| A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge | Q35531454 | ||
| A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease | Q36456720 | ||
| Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection | Q36515143 | ||
| Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway | Q38631970 | ||
| Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus | Q39614881 | ||
| Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. | Q39926740 | ||
| Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates | Q40540668 | ||
| Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS. | Q40621400 | ||
| Influence of FcgammaRIIA and MBL polymorphisms on severe acute respiratory syndrome. | Q47721502 | ||
| Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome | Q47742637 | ||
| Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection | Q64120187 | ||
| P921 | main subject | COVID-19 | Q84263196 |
| SARS-CoV-2 | Q82069695 | ||
| P577 | publication date | 2020-04-21 | |
| P1433 | published in | Nature Reviews Immunology | Q43355 |
| P1476 | title | The potential danger of suboptimal antibody responses in COVID-19 |
| Q98778482 | A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes |
| Q97566482 | A perspective on potential antibody-dependent enhancement of SARS-CoV-2 |
| Q99623808 | Age-Related Differences in Immunological Responses to SARS-CoV-2 |
| Q99240439 | Antibody response to SARS-Co-V-2, diagnostic and therapeutic implications |
| Q99633024 | COVID-19 and its impact on neurological manifestations and mental health: the present scenario |
| Q97569068 | COVID-19 vaccine development and a potential nanomaterial path forward |
| Q107203534 | Comprehensive Transcriptomic Analysis of COVID-19 Blood, Lung, and Airway |
| Q95603877 | Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals |
| Q96576972 | Convergent antibody responses to SARS-CoV-2 in convalescent individuals |
| Q95300582 | Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody |
| Q96163477 | Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective |
| Q103803963 | Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform |
| Q100750398 | Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2 |
| Q94939093 | Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients - a perspective |
| Q98770744 | Development of vaccines for SARS-CoV-2 |
| Q101403330 | Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum |
| Q102075551 | Eliciting B cell immunity against infectious diseases using nanovaccines |
| Q99609040 | Expedited COVID-19 vaccine trials: a rat-race with challenges and ethical issues |
| Q98224836 | High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects |
| Q98467294 | How Signaling Games Explain Mimicry at Many Levels: From Viral Epidemiology to Human Sociology |
| Q98464576 | Immune Response and COVID-19: A mirror image of Sepsis |
| Q96953625 | Immune Response, Inflammation, and the Clinical Spectrum of COVID-19 |
| Q96647319 | Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation |
| Q101237621 | Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans |
| Q97535447 | Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature |
| Q97553323 | Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease |
| Q99400178 | On the genetics and immunopathogenesis of COVID-19 |
| Q96762059 | Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19 |
| Q99624588 | Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine |
| Q98730822 | Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development |
| Q97518859 | Reappearance of effector T cells is associated with recovery from COVID-19 |
| Q98228950 | Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient |
| Q110355732 | SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release |
| Q98394889 | Single-cell landscape of immunological responses in patients with COVID-19 |
| Q98663509 | Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19 |
| Q99711532 | The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development |
| Q96647253 | The Zebrafish Disease and Drug Screening Model: A Strong Ally Against Covid-19 |
| Q98182389 | The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19) |
| Q101166851 | The immune roadmap for understanding multi-system inflammatory syndrome in children: opportunities and challenges |
| Q99567215 | Transcriptomic analysis of COVID‑19 lungs and bronchoalveolar lavage fluid samples reveals predominant B cell activation responses to infection |
Search more.